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In vitro studies suggest that the mitochondrial glycer-
ol-3-phosphate acyltransferase-1 (mtGPAT1) isoform
catalyzes the initial and rate-controlling step in glycero-
lipid synthesis and aids in partitioning acyl-CoAs to-
ward triacylglycerol synthesis and away from degrada-
tive pathways. To determine whether the absence of
mtGPAT1 would increase oxidation of acyl-CoAs and
restrict the development of hepatic steatosis, we fed
wild type and mtGPAT1/ mice a diet high in fat and
sucrose (HH) for 4 months to induce the development of
obesity and a fatty liver. Control mice were fed a diet
low in fat and sucrose (LL). With the HH diet, absence of
mtGPAT1 resulted in increased partitioning of acyl-
CoAs toward oxidative pathways, demonstrated by 60%
lower hepatic triacylglycerol content and 2-fold in-
creases in plasma -hydroxybutyrate, acylcarnitines,
and hepatic mRNA expression of mitochondrial HMG-
CoA synthase. Despite the increase in fatty acid oxida-
tion, liver acyl-CoA levels were 3-fold higher in the mt-
GPAT1/ mice fed both diets. A lack of difference in
CPT1 and FAS mRNA expression between genotypes
suggested that the increased acyl-CoA content was not
because of increased de novo synthesis, but instead, to
an impaired ability to use long-chain acyl-CoAs derived
from the diet, even when the dietary fat content was low.
Hyperinsulinemia and reduced glucose tolerance on the
HH diet was greater in the mtGPAT1/ mice, which did
not suppress the expression of the gluconeogenic genes
glucose-6-phosphatase and phosphoenolpyruvate car-
boxykinase. This study demonstrates that mtGPAT1 is
essential for normal acyl-CoA metabolism, and that the
absence of hepatic mtGPAT1 results in the partitioning
of fatty acids away from triacylglycerol synthesis and
toward oxidation and ketogenesis.
Hepatic steatosis, a feature of the metabolic syndrome, is a
precursor for hepatosteatitis, cirrhosis, and liver failure (1).
The initial and rate-controlling step in triacylglycerol synthesis
is catalyzed by glycerol-3-phosphate acyltransferase (GPAT),1
which uses long-chain acyl-CoAs to acylate glycerol 3-phos-
phate (2). Three GPAT activities have been identified in mam-
malian tissues, one in the endoplasmic reticulum (microsomal
GPAT), and two in the mitochondria, mtGPAT1 and mtGPAT2
(2, 3). Although the independent roles of the three GPAT iso-
forms have not been established, the mtGPAT1 appears to be
an important contributor to triacylglycerol synthesis. For ex-
ample, mtGPAT1 activity and mRNA expression are up-regu-
lated nutritionally and hormonally when excess calories are
available from either dietary fat or carbohydrate (4–6). Con-
versely, mice that lack mtGPAT1 have a lower hepatic content
of triacylglycerol and a lower rate of very low density lipopro-
tein secretion compared with wild type mice (7).
Directing acyl-CoAs toward either oxidative or synthetic
pathways is key in the regulation of cellular energy metabo-
lism and triacylglycerol accumulation. Both mtGPAT1 and
carnitine palmitoyltransferase-1, the rate-limiting step for
-oxidation, are intrinsic enzymes of the outer mitochondrial
membrane where their reciprocal regulation by AMP-acti-
vated protein kinase (AMPK) would allow them to play coor-
dinated roles in directing the fate of acyl-CoAs. In vitro
studies show that AMPK phosphorylates acetyl-CoA carbox-
ylase, thereby decreasing the product of acetyl-CoA carbox-
ylase, malonyl-CoA, the allosteric inhibitor of carnitine
palmitoyltransferase-1 (8). Concomitantly, AMPK inhibits
mtGPAT1, decreasing the entry of acyl-CoAs into the path-
way of glycerolipid synthesis (9–11).
When fed diets high in fat and sucrose C57BL/6J mice
develop severe obesity, hyperglycemia, and hyperinsulinemia
(12), and hepatic mtGPAT1 specific activity increases 2-fold
(13). Overexpression of mtGPAT1 in rat hepatocytes in-
creases both triacylglycerol mass and the incorporation of
[14C]oleate into triacylglycerol, while decreasing [14C]oleate
incorporation into oxidation products (13, 14). Thus, because
the mitochondrial isoform of GPAT comprises 30–50% of
total hepatic GPAT activity, we reasoned that the absence of
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-oxidation, even when mice are fed a diet designed to pro-
mote obesity and hepatic steatosis.
MATERIALS AND METHODS
Animals and Diets—Animal protocols were approved by the Univer-
sity of North Carolina at Chapel Hill Institutional Animal Care and Use
Committee. Generation of mtGPAT1/ mice was previously described
(7). F1 mice were crossed six times with C57BL/6J mice to transfer the
null mtGPAT1 mutation onto a C57BL/6J genetic background (99%).
Heterozygotes were then intercrossed to obtain mtGPAT1 wild type,
heterozygous, and homozygous knock-out mtGPAT1 mice. Because the
male and female mtGPAT1/ mice had similar phenotypes, unless
otherwise noted, only data from males are shown. Mice were housed in
a pathogen-free barrier facility on a 12-h light/dark cycle and had free
access to water and food. Weaned mice were fed Prolab RMH 3000 SP76
chow (26.0% kcal protein, 14% kcal fat, and 60% kcal carbohydrate).
From ages 2 to 6 months they were fed either a high fat/high sucrose
(HH) diet that results in marked lipogenesis, triacylglycerol synthesis,
hyperlipidemia, obesity, and insulin resistance (12, 15–17) or the com-
plementary low fat/low sucrose (LL) diet (12). The high sucrose content
of the diet promotes hepatic lipogenesis by increasing insulin secretion
and activation of SREBP1c and by by-passing the rate-limiting step of
glycolysis, phosphofructokinase, thereby increasing the production of
glycerol 3-phosphate (18). The diets were LL: Research Diet D12328
(16.4% kcal protein, 73.1% kcal carbohydrate (611 g/kg corn starch, 124
g/kg maltodextrin 10), 10.5% kcal fat (29.3 g/kg coconut oil, 18.3 g/kg
soybean oil)) and HH: Research Diet D12331 (16.4% kcal protein, 25.5%
kcal carbohydrate (175 g/kg sucrose, 170 g/kg maltodextrin 10), 58%
kcal fat (333.5 g/kg coconut oil, 25 g/kg soybean oil)).
Blood Chemistries and Lipids—Mice were fasted for 4–6 h before
blood collection. Plasma triacylglycerol (triglyceride, Stanbio, Boerne,
TX), total cholesterol (cholesterol CII, Wako Diagnostics, Richmond,
VA), free fatty acids (NEFA, Wako Diagnostics, Richmond, VA), glucose
(glucose CII, Wako Diagnostics), and -hydroxybutyrate (Wako Diag-
nostics) were determined by enzymatic colorimetric methods. Insulin
(ultrasensitive rat insulin enzyme-linked immunosorbent assay, Crys-
tal Chemical, Chicago, IL) and leptin (mouse leptin enzyme-linked
immunosorbent assay, Crystal Chemical) were determined by enzyme-
linked immunosorbent assay. For the glucose tolerance test, mice were
injected intraperitoneally with 1 mg of glucose/g body weight. Plasma
was collected at time 0, and at 15, 30, 60, 90, and 120 min after the
glucose injection. To calculate the insulin resistance index, the areas
under the glucose and insulin curves in the glucose tolerance test were
calculated by multiplying the cumulative mean height of the glucose
values (1 mg/ml  1 cm) and the insulin values (1 ng/ml  1 cm) by time
(60 min  1 cm) (19). The insulin resistance index is the product of the
areas under the glucose and the insulin curves.
Liver Triacylglycerol and Lysophosphatidic Content—Liver was ho-
mogenized in 10 mM Tris, pH 7.4, 250 mM sucrose, 1 mM dithiothreitol,
and 1 mM EDTA. Lipids were extracted from the homogenate with
chloroform/methanol (2/1, v/v) (20). For triacylglycerol measurements,
total lipid extracts were dried under N2 gas, resuspended in isopropyl
alcohol, 1% Triton X-100 and analyzed colorimetrically as described
above. To measure lysophosphatidic acid content, 100 mg of liver was
homogenized in chloroform/methanol (1:1, v/v) with 1 nM C17-lysophos-
phatidic acid internal standard. After phase separation with distilled
H2O, samples were homogenized and centrifuged, and the methanol/
water phase was collected. The supernatant was applied to conditioned
Waters Oasis MAX extraction cartridges (Waters Corp., Milford, MA)
and after a washing step, lysophosphatidic acid was eluted using meth-
anol. Individual lysophosphatidic acid derivatives were measured using
LC/MS/MS analysis. Total lysophosphatidic acid content was expressed
as the sum of individual species.
Liver Fatty Acyl-CoA Content—For solid-phase extraction of me-
dium, long-chain, and very long-chain fatty acyl-CoAs (21), 100 mg of
liver together with a C17:0 acyl-CoA-ester internal standard was ho-
mogenized on ice in 50 mM KH2PO4, 50% 2-propanol. An equal volume
of acetonitrile and 1/32 of the final volume of (NH4)2SO4 was added, the
emulsion was vortexed, and the supernatant was separated by centrif-
ugation. The supernatant was diluted with 100 mM KH2PO4 and puri-
fied using Oligonucleotide Purification Cartridges (Applied Biosystems,
Foster City, CA). Following a drying step, fatty acyl-CoA fractions were
dissolved in methanol/H2O (1:1, v/v) and subjected to LC/MS/MS anal-
ysis. A turbo ion spray source was interfaced with an API 3000 tandem
mass spectrometer (Applied Biosystems, Foster City, CA) in conjunc-
tion with two PerkinElmer 200 Series micro pumps and a 200 Series
autosampler (PerkinElmer Life Sciences). The transition pairs
[M-2H]2:[M-H-80] (Q1 and Q3) were monitored in MRM (multiple
reaction monitoring) mode for each fatty acyl-CoA metabolite. Total
fatty acyl-CoA content is expressed as the sum of individual species.
Liver Acylcarnitine Content—Liver specimens (75 mg) were homog-
enized in 9 volumes of de-ionized water using a Potter-Everhelm Teflon-
glass homogenizer. The mixture was then centrifuged at 14,000  g for
10 min at 4 °C, and 50 l of the supernatant was supplemented with 2.5
l of a mixture of internal standards containing 0.1 nmol/l of d3-
acetylcarnitine  0.02 nmol/l of d3-propionylcarnitine  0.02 nmol/l
of d3-butyrylcarnitine  0.02 nmol/l of d3-octanoylcarnitine  0.04
nmol/l of d3-palmitoylcarnitine. Acylcarnitine esters were extracted
(22, 23) and measured by direct injection electrospray tandem mass
spectrometry using a Quattro Micro LC-MS system (Waters-Micro-
mass, Milford, MA) equipped with a model HTS-PAL autosampler
(Leap Technologies, Carrboro, NC), a model 1100 high pressure liquid
chromatography solvent delivery system (Agilent Technologies), and a
data system running MassLynx software.
Histology—Mouse tissues were fixed in 4% phosphate-buffered
paraformaldehyde (pH 7.4), embedded in paraffin, sectioned (5 m),
and stained with hematoxylin and eosin.
Quantitative Reverse Transcriptase PCR-based Gene Expression
Analysis—RNA was isolated from frozen liver samples using a commer-
cially available kit (Qiagen RNeasy kit, Qiagen Inc., Valencia, CA) in
combination with DNase digest treatment. Then 1.5 g of total RNA
was reverse transcribed (Stratagene, La Jolla, CA) with random oligo
primers. PCR was performed with a DNA Engine Opticon 2 System (MJ
Research, Boston, MA) using the SYBR Green QPCR dye kit (Strat-
agene, La Jolla, CA). Long-chain acyl-CoA dehydrogenase, FAS,
SREBP1c, PPAR, PPAR, glucose-6-phosphatase, and 18 S rRNA
were amplified using this system. Product specificity was verified by
running products on an agarose gel. Reactions were performed in du-
plicate and messenger RNA levels (CT values) normalized to 18 S
rRNA were expressed using the comparative method. 18 S rRNA levels
showed no statistical difference between groups.
Quantitative reverse transcriptase-PCR for peroxisome proliferator-
activated receptor- coactivator-1, mitochondrial HMG-CoA synthase,
CPT1, PEPCK, mtGPAT1, ACO, and SCD1 was performed using an
ABI PRISM 7000 Sequence Detection System instrument and Taq-
Man® Universal PCR Master Mix used according to the manufacturer’s
specifications (Applied Biosystems, Inc., Foster City, CA). Reactions
were performed in triplicate and contained 20 ng of cDNA as template,
900 nM forward and reverse primers, and 200 nM probe. Target gene
expression was normalized to 18 S rRNA levels, which were assayed by
multiplexing with the manufacturer’s 5 VIC-labeled, primer-limited 18
S endogenous control premix. Primers and 5 FAM-labeled TaqMan
probes were purchased as pre-validated assays (ABI) or designed using
Primer Express® software and sequences available in GenBankTM.
Relative quantification of target genes was calculated using the 2CT
method (24), which was validated for each primer/probe set using a
6-point serial standard curve as described previously (25). Derivation of
the 2CT equation has been described in Applied Biosystems User
Bulletin No. 2 (P/N 4303859).
Statistics—Data were analyzed by Student’s t test or by analysis of
variance (ANOVA). ANOVA was performed on data at a minimum p 	
0.05 threshold and a multiple comparison Fischer post-hoc test was
performed to evaluate differences between genotypes and dietary treat-
ments with JMP software version 5 (SAS Institute Inc., Cary, NC). Data
are shown as mean 
 S.E.
RESULTS
The High Fat/High Sucrose Diet Increased Weight Gain and
Plasma Lipids—To induce lipogenesis, 2-month-old male mtG-
PAT1 / (wild type), / (heterozygote), and / (deficient)
mice were fed either a high fat/high sucrose or a low fat/low
sucrose control diet for 4 months. Body weights increased 80%
on the HH diet and 30% on the LL diet, as did all measured fat
pad weights (Fig. 1). When expressed as a percent of total body
weight, isolated gonadal and retroperitoneal fat pads were
2.5-fold greater, and brown adipose tissue was 1.4-fold greater
in mice fed the HH diet. Adipose tissue histology revealed
larger adipocytes from gonadal tissue in mice fed the HH diet
than in mice fed the LL diet (Fig. 2, C and D). Correlating with
the development of obesity in mice fed the HH diet, the plasma
leptin concentrations were 5-fold higher, and, similar to
changes previously reported on this diet (12), plasma concen-
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trations of triacylglycerol, cholesterol, free fatty acid, glucose,
and insulin were elevated (Table I).
mtGPAT1/ Mice Were Not Resistant to Diet-induced Obe-
sity—Despite the marked effect that the HH diet had on weight
gain and fat pad weight, there were no differences in terminal
body weight or individual fat pad weight by genotype (Fig. 1),
and the weights of liver, kidney, and skeletal (soleus and ex-
tensor digitorum longus) muscle did not differ between geno-
types on either diet (data not shown). The lack of difference
between genotypes in percent of lean and fat body mass was
confirmed by densitometry (PIXImus, Faxitron X-ray Corpora-
tion) (data not shown). Adipocyte size was similar between
genotypes in both LL and HH fed mice (Fig. 2, A–D). Consistent
with the lack of difference in fat pad weights, the plasma leptin
concentrations did not differ between genotypes (Table I).
mtGPAT1/ Mice Accumulate Less Hepatic Triacylglycerol
and Lysophosphatidic Acid—In vitro and animal studies show
a direct correlation between increased mtGPAT1 activity and
triacylglycerol accumulation in liver (13, 26), as well as hyper-
lipidemia in mice fed the HH diet (12). Thus, we expected that
absent mtGPAT1 would result in lower liver triacylglycerol
content and lower plasma lipids. Although plasma triacylglyc-
erol values did not differ between genotypes fed the HH diet,
cholesterol concentrations were 20% lower in the mtGPAT1/
mice (Table I).
Hepatocytes from mtGPAT1/ mice fed the HH diet con-
tained smaller lipid vacuoles than the corresponding wild type
controls, and triacylglycerol content in mtGPAT1/ liver was
60% lower on the HH diet and 40% lower on the LL diet (Fig. 3).
As expected, lysophosphatidic acid, the product of mtGPAT1,
was 50% lower in mtGPAT1/ mice (Fig. 4), and the C16:0,
C16:1, and C18:1-lysophosphatidic acid species were decreased
most strongly in mtGPAT1/ mice compared with wild type
controls on both diets (data not shown). Thus, in liver from
mtGPAT1/ mice, less acyl-CoA is channeled toward triacyl-
glycerol synthesis.
Ketogenesis Is Increased in mtGPAT1/ Mice—A conse-
quence of reduced partitioning of fatty acid into triacylglyc-
erol synthesis could be increased oxidation and ketogenesis,
the latter directly correlated with -oxidation. With the LL
diet, no difference in plasma -hydroxybutyrate values was
observed between wild type and mtGPAT1/ mice. With the
HH diet, however, -hydroxybutyrate increased in both gen-
otypes, and was 2-fold higher in the mtGPAT1/ mice than
in the wild type controls (Table I). In the mtGPAT1/ mice,
the increase in -hydroxybutyrate was associated with a
2-fold increase in the expression of HMG-CoA synthase, the
rate-limiting enzyme in ketogenesis (Table II). Expression of
PPAR, and its mitochondrial targets CPT1 and long-chain
acyl-CoA dehydrogenase did not differ between genotypes on
either diet, although there was a diet-induced increase in
peroxisomal acyl-CoA oxidase. Thus, the robust changes in
acyl-CoA partitioning were not associated with a global in-
duction of PPAR-targeted genes.
Hepatic Acyl-CoA Content Is Increased in mtGPAT1/
Mice—If the absence of mtGPAT1 allows more acyl-CoA to
enter the pathways of -oxidation and ketogenesis, one might
expect to find lower plasma-free fatty acid and hepatic acyl-
CoA concentrations relative to wild type controls. As pre-
dicted, plasma-free fatty acid in mtGPAT1/ mice fed the
HH diet was about 10% lower (Table I). Unexpectedly, how-
ever, the liver content of acyl-CoA in mtGPAT1/ mice fed
either diet was 3-fold higher than in wild type controls (Fig.
5A), and the most prevalent liver acyl-CoA species, 16:0, 16:1,
FIG. 1. mtGPAT1/ mice are not resistant to diet-induced obe-
sity. A, weight gain of male mice on LL (/, n  11; /, n  12; /,
n  10) and HH (/, n  13; /, n  11; , n  9) diets fed from 2
to 6 months of age. B, fat pad weights as percent of total body weight of
male mice after 4 months on LL (/, n  11; /, n  10) diet and on
HH (/, n  7; /, n  6) diets. Gonadal (GON), retroperitoneal
(RT), inguinal (ING), brown adipose tissue (BAT) are indicated. ND, not
determined
FIG. 2. HH feeding increases lipid accumulation in adipose
tissue. Morphology of interscapular brown adipose tissue from mt-
GPAT1/ and wild type mice fed (A) LL and (B) HH diets for 4 months.
Morphology of gonadal fat from mtGPAT1/ and wild type mice fed (C)
LL or (D) HH diets for 4 months. Paraffin sections are stained with
hematoxylin and eosin.
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18:0, 18:1, and 18:2, were 2.5–6-fold more abundant in the
mtGPAT1/ mice (Fig. 5, B and C). This distribution of
acyl-CoAs differed from the fatty acid composition of both
diets (Fig. 4, D and E), but the predominant acyl-CoA species
were similar to the long-chain fatty acid composition of the
diet. To ascertain whether the long-chain acyl-CoAs might
originate in the diet or from newly synthesized fatty acid, we
examined the expression of SREBP-1c and its target gene,
fatty acid synthase; neither differed between genotypes (Ta-
ble II). The lack of increase in FAS mRNA expression in the
mtGPAT1/ mice suggests that the pathway of de novo fatty
acid synthesis was not up-regulated. Because medium-chain
fatty acids are preferentially oxidized, the accumulation of
long-chain acyl-CoAs in mtGPAT1/ mouse liver reflects the
inability of the mitochondria to handle excess fatty acids
when mtGPAT1 is not available to divert them toward glyc-
erolipid synthesis. Interestingly, although 18:1-CoA was the
most abundant acyl-CoA identified on both the HH and LL
diets, the expression of stearoyl-CoA desaturase (SCD), the
enzyme that forms oleoyl-CoA, was decreased 50% in the HH
fed mtGPAT1/ mice (Table II), suggesting that an eleva-
tion in oleoyl-CoA might down-regulate SCD-1.
Diet, fatty acid, and acyl-CoAs regulate gene transcription
controlled by SREBP, HNF4, and PPAR- and - (27). Com-
pared with mice fed the LL diet, mice fed the HH diet showed
TABLE I
Plasma values for mtGPAT1/ and wild-type mice fed HH or LL diets
Numbers of samples analyzed for each measurement are in parentheses. Values are presented as mean 
 S.E, analyzed by Student t-test. Values
with different superscript numbers differ significantly; p value 	 0.05.
LL HH p valuea
Genotype / / / / Geno-type diet
Leptin (ng/ml) 5.8 
 1.11 (10) 5.8 
 11 (8) 28.0 
 2.12 (10) 27.5 
 3.12 (7) NS 0.001
Triacylglycerol (mg/dl) 39 
 21 (10) 35 
 31 (10) 44 
 42,3 (13) 43 
 22,3 (8) NS 	0.05
Cholesterol (mg/dl) 80 
 71 (9) 76 
 51 (9) 166 
 52 (13) 133 
 83 (8) 0.02 0.0001
FFA (mM) 0.41 
 0.061,2 (10) 0.36 
 0.041,3 (9) 0.59 
 0.064 (9) 0.53 
 0.072,3,4 (8) 0.04 0.03
-Hydroxybutyrate (M) 138 
 431 (5) 233 
 591 (5) 386 
 372 (9) 777 
 1123 (10) 0.003 	0.0001
Glucose (mg/dl) 127 
 81 (10) 130 
 61 (13) 174 
 182 (7) 193 
 102 (9) NS 	0.001
Insulin (ng/dl) 0.62 
 0.181 (10) 0.55 
 0.181 (13) 1.09 
 0.222 (7) 1.87 
 0.243 (9) 0.03 	0.008
IR indexb 3.8 
 0.91 (10) 2.8 
 0.41 (13) 10.1 
 2.62 (7) 17.2 
 3.62 (9) NS 0.0001
a Calculated by ANOVA; NS, no statistically significant difference.
b IR index (insulin resistance index) was calculated as the product of the areas under the glucose and insulin curves as described under
“Materials and Methods.”
FIG. 3. mtGPAT1/ mice accumulate less hepatic triacylglyc-
erol. Representative liver paraffin sections stained with hematoxylin
and eosin at 6 months from mtGPAT1/ and wild type mice fed (A) LL
and (B) HH diets for 4 months. C, liver triacylglycerol content from mice
fed LL (/, n  5; /, n  4) or HH (/, n  6; /, n  5) diets.
Data are shown are mean 
 S.E.; columns identified with different
letters differ significantly (p value 	 0.05, ANOVA).
FIG. 4. Liver lysophosphatidic acid is low in mtGPAT1/ mice.
Total liver acyl-CoA values at 6 months from mtGPAT1/ and wild
type mice fed LL (/, n  5; /, n  4) and HH diets (/, n  6;
/, n  5) for 4 months. Data shown are mean 
 S.E. *, p value 	 0.05
compared with wild type by Student’s t test.
TABLE II
Gene expression in liver from mtGPAT1/ and WT mice
fed HH and LL diets
Total RNA was extracted from liver of wild type (/) and GPAT null
(/) mice fed on a HH or LL diet (n  5 for HH /, n  6 for all other
groups). Gene expression levels were determined by real-time quanti-
tative PCR as described under “Materials and Methods” and are pre-
sented as –fold change (mean 
 S.E.) relative to the LL / controls.
Results were analyzed by ANOVA and Student’s t test. Significant
differences (p value 	 0.05) between groups are indicated by dissimilar
superscript numbers.
LL HH
Genotype / / / /
mtGPAT1 1.0 
 0.151 ND1 1.89 
 0.262 ND
mtHS2b 1.0 
 0.181 1.0 
 0.081 0.88 
 0.221 1.74 
 0.152
CPT1 1.0 
 0.20 0.75 
 0.12 1.03 
 0.18 0.75 
 0.07
LCAD 1.0 
 0.38 0.91 
 0.23 0.99 
 0.18 1.21 
 0.13
ACO 1.0 
 0.181 0.87 
 0.091 2.49 
 0.392 1.81 
 0.192
PPAR 1.0 
 0.25 0.63 
 0.05 0.95 
 0.13 0.81 
 0.14
PGC-1 1.0 
 0.09 1.39 
 0.29 1.28 
 0.24 0.94 
 0.21
PPAR 1.0 
 0.291 1.22 
 0.431,2 2.18 
 0.442,3 1.97 
 0.462,3
SREBP1c 1.0 
 0.16 1.39 
 0.45 1.17 
 0.30 1.43 
 0.27
FAS 1.0 
 0.28 1.04 
 0.25 1.26 
 0.57 1.86 
 0.92
SCD1 1.0 
 0.271 1.23 
 0.261 0.95 
 0.191 0.44 
 0.072
G6P 1.0 
 0.181 1.33 
 0.321 0.35 
 0.122 0.80 
 0.171,2
PEPCK 1.0 
 0.09 1.14 
 0.05 0.90 
 0.15 0.84 
 0.23
a ND, not determined.
b The abbreviations used in the table are: mitochondrial 3-hydroxy-
3-methylglutaryl-CoA synthase (mtHS2), acyl-CoA oxidase (ACO), car-
nitine palmitoyltransferase-1 (CPT1), long-chain acyl-CoA dehydrogen-
ase (LCAD), PPAR  and , peroxisome proliferator-activated
receptor- coactivator-1 (PGC-1), PEPCK, SREBP1c, FAS, SCD1,
glucose-6-phosphatase (G6P).
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an increase in hepatic expression of PPAR, which is up-regu-
lated in liver by high fat feeding (28), but no change in PPAR,
SREBP1c, or peroxisome proliferator-activated receptor- co-
activator-1 (Table II). The expression of these transcription
factors did not differ between genotypes.
Hepatic Acylcarnitines Increase in mtGPAT1/ Mice—To
gain a more comprehensive analysis of hepatic fatty acid
catabolism we profiled mitochondrial-derived acylcarnitine
esters. These analytes reflect mitochondrial accumulation of
fatty acyl-CoAs and dicarboxylic acids and thus provide in-
formation regarding substrate flux through specific steps of
the -oxidation spiral. In both control and mtGPAT1/ mice,
the HH diet increased hepatic accumulation of medium-chain
(C6, C8, and C10) acylcarnitine derivatives (Fig. 6, A and B),
consistent with high mitochondrial uptake and catabolism of
medium-chain fatty acids. The HH diet also increased hepatic
levels of -OH-butyrylcarnitine, a marker of accelerated
-oxidation and ketogenesis. Whereas most medium-chain
metabolites were unaffected by genotype, diet-induced accu-
mulation of the dicarboxylic analyte, C8-DC, the long-chain
acylcarnitines (C16, C18, C18:1, and C18:2), and the long-
chain hydroxy-acylcarnitines (C16-OH, C18-OH, and C18:1-
OH) were greater in liver from the mtGPAT1/ mice com-
pared with control mice.
High Fat Feeding Induces Changes in Insulin Responsive-
ness in mtGPAT1/ Mice—The HH diet resulted in higher
fasting plasma glucose and insulin in both genotypes (Table I).
Plasma insulin values were 70% higher in the mtGPAT1/
mice compared with wild type mice (Table I), suggesting an
increase in insulin resistance. To determine the response of the
mtGPAT1/ and wild type mice to a glucose load, a glucose
tolerance test was performed. The rates of glucose and insulin
clearance after a glucose load did not differ between genotypes
that had been fed the LL diet (Fig. 7, A and C). In contrast to
the LL diet, the HH fed mice developed fasting hyperglycemia
accompanied by pronounced hyperinsulinemia and a reduced
glucose tolerance with a slower rate of glucose clearance for
mtGPAT1/ mice (Fig. 7, B and D). Plasma insulin values
tended to be higher in mtGPAT1/ mice, but were not signif-
icantly different from wild type animals. Although the calcu-
lated insulin resistance index was 2.7- and 6.1-fold higher,
respectively, in both genotypes fed the HH compared with the
LL diet, it did not differ significantly by genotype (Table I).
Despite glucose intolerance at a whole-body level, the HH diet
FIG. 5. Liver acyl-CoA content is elevated in mtGPAT1/ mice. A, total liver acyl-CoA values from mtGPAT1/ and wild type mice fed
LL (/, n  5; /, n  4) and HH diets (/, n  6; /, n  5) for 4 months. B and C, liver acyl-CoA composition of mice fed the LL diet (/,
n  5; /, n  4) (B) or the HH diet (/, n  6; /, n  5) for 4 months (C). D, fatty acid composition of LL diet: Research Diets D12328. E,
fatty acid composition of HH diet: Research Diets D12331. Data are shown as mean 
 S.E.; columns identified with different letters or the asterisk
(*) differ significantly (p value 	 0.05, Student’s t test).
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still suppressed glucose-6-phosphatase, but not PEPCK, in
wild type controls (Table II). In contrast, the mtGPAT1/ mice
failed to down-regulate glucose-6-phosphatase in response to
the HH diet, suggesting that hepatic insulin resistance was
more severe when mtGPAT1 was absent (Table II).
DISCUSSION
Obesity and dysregulation of lipid metabolism is associated
with hepatic steatosis and hyperlipidemia (29). mtGPAT1,
which catalyzes the initial step in triacylglycerol synthesis, is a
key regulator of triacylglycerol metabolism in liver (2), where it
comprises 30–50% of total GPAT activity (2). The expression of
mtGPAT1 is regulated both nutritionally and hormonally in a
manner consistent with a prominent role in triacylglycerol
synthesis (30). For example, mtGPAT1 mRNA expression in-
creases 19-fold 6 h after insulin is given to streptozotocin-
diabetic mice, and 20-fold when food restricted mice are refed a
high-carbohydrate, fat-free diet (4). The up-regulation by insu-
lin is mediated by SREBP-1c, which also acts to increase the
expression of lipogenic target genes like acetyl-CoA carboxyl-
ase and FAS (31, 32).
Because they are intrinsic proteins of the outer mitochon-
drial membrane, it has been hypothesized that mtGPAT1 and
CPT1 control the partitioning of acyl-CoAs between incorpora-
tion into glycerolipid synthesis and -oxidation. mtGPAT1 and
carnitine palmitoyltransferase-1 are reciprocally regulated by
AMPK that phosphorylates and inhibits acetyl-CoA carboxyl-
ase, thereby decreasing the malonyl-CoA-mediated allosteric
FIG. 6. Long-chain acylcarnitines
are high in mtGPAT1/ mice. Hepatic
acylcarnitine values from mtGPAT1/
and wild type mice fed LL (/, n  5;
/, n  4) and HH diets (/, n  6;
/, n  5) for 4 months. A, major acyl-
carnitine species; B, minor acylcarnitine
species. The data are shown as mean 

S.E. Significant differences are indicated
by (a) for diet, (b) for genotype, and (c) for
an interaction between diet and genotype
(p value 	 0.05, ANOVA). OH-, hydroxyl;
DC, dicarboxylic. WT, wild type; KO,
knock-out.
FIG. 7. mtGPAT1/ mice have reduced glucose tolerance with
HH feeding. A, plasma glucose concentrations during an intraperito-
neal glucose tolerance test on male and female mice fed the LL diet
(/, n  10; /, n  13); or B, the HH diet (/, n  7; /, n  9)
for 4 months. C, plasma insulin concentrations during an intraperito-
neal glucose tolerance on male and female mice fed the LL diet (/,
n  10; /, n  13); or D, the HH diet (/, n  7; /, n  9) for 4
months. Data shown are mean 
 S.E.; values identified by (*) differ
significantly (p value 	 0.05, Student’s t test).
Mitochondrial GPAT Metabolizes Excess Acyl-CoAs25634
inhibition of carnitine palmitoyltransferase-1 (10). AMPK also
inhibits mtGPAT1 activity, decreasing the incorporation of la-
beled [14C]oleate and [3H]glycerol incorporation into triacyl-
glycerol and increasing labeled [14C]oleate incorporation into
acid soluble metabolites (9). Overexpressing rat mtGPAT1 in
Chinese hamster ovary and HEK293 cells increases triacyl-
glycerol mass and the incorporation of labeled [14C]oleate into
triacylglycerol (26). In rat hepatocytes, adenoviral-mediated
overexpression of mouse or rat mtGPAT1 decreases labeled
[14C]oleate incorporation into oxidation pathways and in-
creases [14C]oleate incorporation into triacylglycerol (13, 14).
Because these in vitro studies suggest that mtGPAT1 par-
titions acyl-CoAs toward synthetic and away from degrada-
tive pathways, we examined the physiological consequences
of absent mtGPAT1 on acyl-CoA partitioning. mtGPAT1/
mice were fed a high fat/high sucrose diet to promote the
development of hepatic lipogenesis, triacylglycerol synthesis,
and obesity (12, 15, 17, 33). A previous study showed that
when mice were fed a high fat (lard)/high sucrose diet for 3
months, hepatic mtGPAT1 mRNA increased 2-fold (13), and
the present study shows a similar increase of mtGPAT1
expression in wild type controls. As expected, the absence of
mtGPAT1 protected against hepatic steatosis. Our data show
that mtGPAT1/ mice fed the HH diet had 60% lower he-
patic triacylglycerol content and increased ketogenesis com-
pared with wild type controls.
Ketogenesis is regulated at three steps: 1) provision of fatty
acids from adipose tissue lipolysis and/or dietary sources; 2) the
CPT1-mediated synthesis of long-chain acylcarnitines for entry
into the mitochondria (or the direct entry of dietary medium-
chain fatty acids); and 3) the activity of mitochondrial HMG-
CoA synthase, which catalyzes the irreversible initial step in
ketogenesis (34). In mtGPAT1/ mice fed the HH diet, the
2-fold increase in plasma -hydroxybutyrate coincided with a
2-fold increase in the expression of mitochondrial HMG-CoA
synthase, suggesting that metabolic changes resulting from the
absence of mtGPAT1 are able to up-regulate HMG-CoA syn-
thase without altering PPAR or its other mitochondrial target
genes, CPT1 and long-chain acyl-CoA dehydrogenase.
The lack of difference in SREBP1c and FAS expression re-
lated to either diet or genotype suggests that the increase in
acyl-CoA content did not result from increased de novo synthe-
sis but, rather, to an inability to use excess acyl-CoAs derived
from dietary fatty acids. Medium-chain fatty acids are prefer-
entially oxidized without conversion to acylcarnitines (35),
whereas the 16- and 18-carbon fatty acids in the HH diet
require CPT1 to convert their acyl-CoA derivatives to acylcar-
nitines. The preferred substrate of mtGPAT1 is 16:0-CoA,
which is esterified at rates 3–10-fold higher than those for
other long-chain acyl-CoAs (36–39). Although some elongation
of medium-chain fatty acids may occur (40), our study strongly
suggests that the normal metabolism of long-chain acyl-CoAs,
even when derived from the LL diet that contains only 10.5%
triacylglycerol, requires the ability of mtGPAT1 to acylate glyc-
erol 3-phosphate. Long-chain acyl-CoAs accumulated when the
synthetic pathway was absent because the amount of acyl-CoA
exceeded the capacity of the mitochondrial oxidation pathway.
Thus, it appears that mtGPAT1 is required to channel excess
long-chain acyl-CoAs toward triacylglycerol synthesis.
In contrast to the medium-chain metabolites, long-chain
acylcarnitines were unchanged by the HH diet, but increased
in the mtGPAT null genotype. Similar to the acyl-CoA profile,
hepatic concentrations of most long-chain acylcarnitines were
highest in the mtGPAT1/ mice fed the HH diet. Thus, as
predicted, deletion of mtGPAT1 appears to increase CPT1-
mediated transport of long-chain acyl-CoAs into the mitochon-
dria. Notably, hepatic content of the long-chain hydroxyl-acyl-
carnitines (e.g. C18:1-OH) was greater in mtGPAT1/ mice
compared with wild type mice. Accumulation of these metabo-
lites, which is thought to reflect a flux limitation at the hy-
droxyacyl-CoA dehydrogenase step, suggests that the long-
chain acyl-CoA supply exceeded the -oxidative capacity of
liver mitochondria. In the aggregate, our results imply that the
mtGPAT1 null condition increases mitochondrial uptake of
long-chain fatty acyl-CoAs via elevated CPT1 activity and/or
increased substrate supply. The excessive -oxidative pressure,
in turn, elicited a compensatory induction of mitochondrial
3-hydroxy-3-methylglutaryl-CoA synthase and a concomitant
rise in hepatic ketogenesis.
Although oleoyl-CoA (18:1-CoA) was the most abundant
acyl-CoA that accumulated, the expression of SCD-1, the
enzyme that catalyzes the de novo synthesis of 18:1-CoA was
50% lower in the livers from the HH fed mtGPAT1/ mice.
SCD-1 transcription is repressed by linoleic acid, arachidonic
acid, and eicosapentaenoic acid (41), and transcription of
SCD-1 is regulated by SREBP1c (42). In vitro studies have
demonstrated that 18:1 and polyunsaturated fatty acids in-
hibit SREBP-mediated transcription and decrease the proc-
essing of mature SREBP proteins (43, 44). Thus, the 3-fold
elevation in 18:1-CoA levels in the liver of the HH fed mtG-
PAT1/ mice may have down-regulated SCD-1 via
SREBP1c. However, the lack of change in FAS, which is also
a target of SREBP1c, suggests that additional factors may
contribute to the specificity of the fatty acid-mediated effect
on SCD1. Alternatively, discordant effects may result from
functionally different metabolic pools of 18:1, one derived
from the diet and the other from de novo synthesis (42).
Similar to a previous report of the HH diet effects on wild
type mice (12), both HH fed mtGPAT1/ and wild type mice
became hyperglycemic and hyperinsulinemic. It has been pro-
posed that reduced insulin sensitivity is related to an increase
in intracellular lipid metabolites of triacylglycerol in liver and
peripheral tissues (45) and that, in muscle, elevated intracel-
lular lipid metabolites such as diacylglycerol or acyl-CoAs in-
duce insulin resistance by activating PKC, which initiates a
serine/threonine kinase cascade that increases serine/threo-
nine phosphorylation and decreases tyrosine phosphorylation
of IRS1/IRS2. The aberrant phosphorylation results in lower
phosphatidylinositol 3-kinase activity, and ultimately dimin-
ishes insulin sensitivity (45). In liver from rats fed a high fat
(safflower oil) diet for 3 days, alterations in the insulin signal-
ing cascade associated with hepatic insulin resistance include
decreased IRS1 and IRS2 phosphotyrosine, decreased IRS1-
and IRS2-phosphatidylinositol 3-kinase activity, decreased
AKT2 and GSK3 activity, and decreased glycogen synthase
activity (46). In these high fat-fed rats, liver acyl-CoAs and
triacylglycerol content are about 3-fold higher and the suppres-
sion of endogenous glucose production is diminished compared
with rats fed a control diet (46). In contrast, the mtGPAT1/
mice fed the HH diet for 4 months in our study had a lower
hepatic triacylglycerol content but higher liver acyl-CoA levels,
higher plasma insulin concentrations, and diminished glucose
tolerance. The differences and commonalities between the
3-day safflower oil diet and the 4-month HH diet suggest that
causative factors of reduced insulin sensitivity may include a
complex association between the dietary source of fatty acid,
the length of exposure, and the lipid metabolite accumulation.
Hepatic acyl-CoA levels in mtGPAT1/ mice fed the LL or
HH diet were about 3-fold higher than in wild type mice, but
PEPCK and glucose-6-phosphatase mRNA was not suppressed
by the HH diet, suggesting the presence of hepatic insulin
resistance. Glucose intolerance in the mtGPAT1/ mice fed
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the HH diet may also be caused by diminished glucose uptake
in peripheral tissues. Because hepatic acyl-CoAs were elevated
while liver triacylglycerol content remained low in the mt-
GPAT1/ mice, further studies will be needed to determine
whether this discordant relationship alters the response of the
liver to insulin.
The major effects of mtGPAT1 deficiency are observed in
liver where this GPAT isoform contributes 50% of total activity;
in contrast, the mtGPAT1 isoform comprises only 10% of total
GPAT activity in adipose tissue (30). In our previous study of
mice fed a low fat chow, the body weight at 5 months and fat
pad weights at 12 months were lower in female, but not male
mtGPAT1/ mice (7). The present study again shows similar
body and fat pad weights of male mtGPAT1/ and wild type
mice, suggesting that the mtGPAT1 isoform may not play an
important role in controlling triacylglycerol storage in fat cells
in male mice.
In the present study we have examined the physiological
consequences of high fat/high sucrose feeding on the hepatic
partitioning of acyl-CoAs in mice that lack mtGPAT1. In-
creased partitioning of acyl-CoAs toward ketogenesis was dem-
onstrated by increased plasma -hydroxybutyrate and in-
creased expression of mtHMG-CoA synthase. In addition, we
found diminished partitioning of acyl-CoAs toward synthetic
pathways demonstrated by reduced hepatic triacylglycerol con-
tent and an elevated content of long-chain acyl-CoAs. The
hepatic acyl-CoAs may have contributed to the repression of
lipogenic gene expression and the induction of ketogenesis.
This study demonstrates the crucial role that mtGPAT1 plays
in controlling the partitioning acyl-CoAs between oxidative and
synthetic pathways and in diverting excess fatty acids toward
triacylglycerol synthesis, even when the diet contains rela-
tively little triacylglycerol.
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